January 1, 2019 Issue of JAMA

January 1/8, 2019, Vol 321, No. 1, Pages 7-114

This Week in JAMA

Highlights

Abstract Full Text

free access has audio

JAMA. 2019;321(1):7-9. doi:10.1001/jama.2018.15135

Podcast: Medical Marketing in the US, Effect of Antiplatelet Co-Pay Vouchers on CVD Outcomes, Linagliptin and CVD in T2DM, and more

Original Investigation

Effect of Medication Co-payment Vouchers on P2Y₁₂ Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial

Tracy Y. Wang, MD, MHS, MSc; Lisa A. Kaltenbach, MS; Christopher P. Cannon, MD; et al.

Abstract Full Text

free access

JAMA. 2019;321(1):44-55. doi:10.1001/jama.2018.19791

This cluster randomized clinical trial evaluated the effect of a voucher to offset medication co-payment costs on persistent P2Y₁₂ inhibitor use and on risk of major adverse cardiovascular events (MACE) at 1 year among adult patients with myocardial infarction discharged with prescriptions for clopidogrel or ticagrelor.

Editorial
Medication Co-payment Vouchers, Adherence With Antiplatelet Therapy, and Adverse Cardiovascular Events After Myocardial Infarction
Cynthia A. Jackevicius, BScPhm, PharmD, MSc; Dennis T. Ko, MD, MSc

JAMA

Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial

Peter J. McCartney, MBChB; Hany Eteiba, MD; Annette M. Maznyczka, MBChB; et al.

Abstract Full Text

free access

JAMA. 2019;321(1):56-68. doi:10.1001/jama.2018.19802

This randomized clinical trial examined whether low-dose intracoronary fibrinolytic therapy with alteplase infused after reperfusion but before stent implant reduced microvascular obstruction among patients with acute ST-segment elevation MI.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Julio Rosenstock, MD; Vlado Perkovic, MBBS, PhD; Odd Erik Johansen, MD, PhD; et al.

Abstract Full Text

free access

JAMA. 2019;321(1):69-79. doi:10.1001/jama.2018.18269

This randomized clinical trial compares the effects of the dipeptidyl peptidase 4 inhibitor linagliptin vs placebo plus usual care on cardiovascular (CV) and renal outcomes in adults with type 2 diabetes and high CV and renal risk.

Research Letter

Primary Care Nurse Practitioners and Physicians in Low-Income and Rural Areas, 2010-2016

Ying Xue, DNSc, RN; Joyce A. Smith, PhD, RN, ANP; Joanne Spetz, PhD

Abstract Full Text

free access

JAMA. 2019;321(1):102-105. doi:10.1001/jama.2018.17944

This study analyzes trends in the distribution of nurse practitioners and primary care physicians in low-income and rural areas.

Special Communication

Medical Marketing in the United States, 1997-2016

Lisa M. Schwartz, MD, MS; Steven Woloshin, MD, MS

Abstract Full Text

free access

JAMA. 2019;321(1):80-96. doi:10.1001/jama.2018.19320

In this study, Schwartz and Woloshin estimate that spending on marketing of prescription drugs, disease awareness, and health and laboratory services in the US increased from $17.7 to $29.9 billion between 1997 and 2016, with the most rapid increase in direct-to-consumer (DTC) advertising of drugs (mainly high-cost biologics and cancer immunotherapy) and disease awareness campaigns.

Editorial
Medical Marketing, Trust, and the Patient-Physician Relationship
Selena E. Ortiz, PhD, MPH; Meredith B. Rosenthal, PhD

JAMA
Medical Marketing in the United States鈥擜 Truly Special Communication
Howard Bauchner, MD; Phil B. Fontanarosa, MD, MBA

JAMA
Editor's Note
A Tribute to Lisa M. Schwartz, MD, MS
Howard Bauchner, MD

JAMA

Viewpoint

Evolving Issues in Oncology

Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion

Susan M. Domchek, MD

Abstract Full Text

JAMA. 2019;321(1):27. doi:10.1001/jama.2018.18942

This Viewpoint reviews the benefits and risks of risk-reducing mastectomy in otherwise healthy women with BRCA1 and BRCA2 mutations to inform discussions about the proceeding with or foregoing the procedure, and it calls for continued research to understand how to better individualize risk and prevent disease nonsurgically.

Humanizing Artificial Intelligence

Sonoo Thadaney Israni, MBA; Abraham Verghese, MD

Abstract Full Text

has audio

JAMA. 2019;321(1):29-30. doi:10.1001/jama.2018.19398

In this Viewpoint, Abraham Verghese and Sonoo Thadaney Israni acknowledge the promise of artificial intelligence (AI) for health care, but argue that developers must work with physicians to ensure that any AI health care system helps clinicians deliver better, more equitable humanistic care, not just more accurate, scientific care.

Podcast: Humanizing Artificial Intelligence

Questions for Artificial Intelligence in Health Care

Thomas M. Maddox, MD, MSc; John S. Rumsfeld, MD, PhD; Philip R. O. Payne, PhD

Abstract Full Text

JAMA. 2019;321(1):31-32. doi:10.1001/jama.2018.18932

This Viewpoint discusses questions that should be addressed to successfully integrate artificial intelligence into clinical care.

Health as a Way of Doing Business

Howard K. Koh, MD, MPH; Sara J. Singer, PhD, MBA; Amy C. Edmondson, PhD

Abstract Full Text

JAMA. 2019;321(1):33-34. doi:10.1001/jama.2018.18935

In this Viewpoint, Howard Koh and colleagues discuss the value the public places on corporations that actively promote community health and environmental responsibility, and innovative business strategies that some corporations have implemented to advance consumer, employee, community, and environmental health.

A Piece of My Mind

The Weight of the White Coat

Anna Goshua, BHSc

Abstract Full Text

JAMA. 2019;321(1):35-36. doi:10.1001/jama.2018.20149

In this narrative medicine essay, a medical student reflects on her first assigned encounter with a patient during which she managed 6 minutes of conversation, short of the 10 minutes required, throwing her into grave self-doubt about her future profession until she enjoys a spontaneous conversation at the Department of Motor Vehicles and realizes that talking is not a test.

Editorial

Medication Co-payment Vouchers, Adherence With Antiplatelet Therapy, and Adverse Cardiovascular Events After Myocardial Infarction

Cynthia A. Jackevicius, BScPhm, PharmD, MSc; Dennis T. Ko, MD, MSc

Abstract Full Text

JAMA. 2019;321(1):37-39. doi:10.1001/jama.2018.20396

Medical Marketing, Trust, and the Patient-Physician Relationship

Selena E. Ortiz, PhD, MPH; Meredith B. Rosenthal, PhD

Abstract Full Text

free access

JAMA. 2019;321(1):40-41. doi:10.1001/jama.2018.19324

Medical Marketing in the United States鈥擜 Truly Special Communication

Howard Bauchner, MD; Phil B. Fontanarosa, MD, MBA

Abstract Full Text

free access

JAMA. 2019;321(1):42-43. doi:10.1001/jama.2018.20505

JAMA Clinical Challenge

A Patient With an Elevated 伪-Fetoprotein Level and Liver Masses

Adam E. Mikolajczyk, MD; Lindsay J. Yassan, MD; Anjana A. Pillai, MD

Abstract Full Text

JAMA. 2019;321(1):97-98. doi:10.1001/jama.2018.18435

A 55-year-old man with several weeks of malaise, a 6.8-kg weight loss, a CT scan with multifocal liver masses and elevated alkaline phosphatase, ALT, and AFP levels had a heterogeneously enhancing pancreatic-tail mass on triple-phase CT. What would you do next?

From The Medical Letter on Drugs and Therapeutics

Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratoses

Abstract Full Text

JAMA. 2019;321(1):99-100. doi:10.1001/jama.2018.16100

This Medical Letter review summarizes the mechanism of action, adverse effects, and dose and administration of hydrogen peroxide 40% topical solution (Eskata), a recently approved treatment for seborrheic keratoses.

Editor's Note

A Tribute to Lisa M. Schwartz, MD, MS

Howard Bauchner, MD

Abstract Full Text

free access

JAMA. 2019;321(1):96. doi:10.1001/jama.2018.20566

Medical News & Perspectives

Black Lung Resurgence Raises New Challenges for Coal Country Physicians

Rebecca Voelker, MSJ

Abstract Full Text

JAMA. 2019;321(1):17-19. doi:10.1001/jama.2018.15966

In this Medical News & Perspectives article, experts discuss how physicians deal with increasing black lung disease cases among Appalachian miners, many at younger ages than in the past.